CClinicalTrials.gg
CompletedNCT02750150TrauCCUpdated Apr 22, 2026

Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients

A Phase 3 interventional study of Freezed-dried plasma and Fresh-frozen plasma in Trauma and Coagulopathy, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University Hospital, Lille · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jul 2013, registered Apr 2016).
Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Knowledge and management of bleeding in severe trauma has changed. A specific coagulopathy is present in 40% of cases. It has a very early onset and this coagulopathy is associated with increased mortality. It must be detected and treated early, as illustrated by the military medical data, from the Iraq war and civilian medicine. However, fresh frozen plasma (FFP) requires a thawing step.The French army has encouraged the development of a freeze-dried plasma of innovative because viral inactivation and universal blood grouping, well tolerated, with a reduced risk of TRALI. This sophisticated therapeutic product can be administered after 6 minutes of reconstitution without the need for cross-matching. Nevertheless, its used is currently reserved for military purpose in overseas operations and needs to be evaluated for civil use. To this end, the investigators need to evaluate the impact on coagulopathy of an immediate availability of plasma.

02

Conditions studied

  • Trauma
  • Coagulopathy
03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

This study's enrollment of 42 is below the median of 52 across 3,239 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Emergency
  • Trauma patient admitted in participating trauma care centers
  • Severe bleeding requiring transfusion with 4 units of red blood cells and 4 emergency plasma.
  • Inclusion performed within the first 6 hours after trauma.

Exclusion criteria

Exclusion Criteria:

  • Patient taking anticoagulants
  • Patients who have received hemostatic treatment during transport (tranexamic -acid excluded)
  • Minor Patient
  • Pregnant or breastfeeding women
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Freezed-dried plasma

    transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)

    Drug: Freezed-dried plasma

  • Active comparator
    Fresh-frozen plasma

    transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)

    Drug: Fresh-frozen plasma

Interventions

  • DrugFreezed-dried plasma

    early transfusion of 4 units of freezed dried plasma

  • DrugFresh-frozen plasma
06

What researchers measure

Primary outcomes

  1. fibrinogen concentration (clauss)

    Time frame: 45 minutes after the admission on day 1 after trauma

Secondary outcomes

  1. time frame of transfusion of 4 plasma

    Time frame: time range between the intention to transfuse plasma and the end of transfusion of 4 plasma within the first 6 hours after admission

07

Study locations

1 site
  • Emergency unit, Salengro hospital,
    Lille, France
08

References and documents

Publications

  • Garrigue D, Godier A, Glacet A, Labreuche J, Kipnis E, Paris C, Duhamel A, Resch E, Bauters A, Machuron F, Renom P, Goldstein P, Tavernier B, Sailliol A, Susen S. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial. J Thromb Haemost. 2018 Mar;16(3):481-489. doi: 10.1111/jth.13929. Epub 2018 Jan 22. PubMed 29274254 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02750150
Lead sponsor
University Hospital, Lille
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Jul 9, 2013
Primary completion
Apr 17, 2016
Completion
Apr 17, 2016
Last update
Apr 22, 2026

Study contacts

Sophie Susen, MD,PhD
study chair · University Hospital, Lille

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion